LEMD1 Inhibitors
LEMD1 inhibitors encompass a variety of chemical compounds that impinge upon different cellular pathways, thereby indirectly attenuating the activity of LEMD1, a protein integral to chromatin organization and nuclear architecture. Compounds such as Rapamycin and Wortmannin exert their inhibitory effect by disrupting the mTOR and PI3K pathways, respectively, which are crucial for cell growth and nuclear signaling, events that are essential for the proper function of LEMD1. Histone deacetylase inhibitors like Trichostatin A can alter the acetylation landscape of histones, impacting chromatin dynamics and potentially affecting the cellular localization or function of LEMD1. Furthermore, inhibitors of the MAPK/ERK pathway, including PD 98059 and U0126, and Hsp90 inhibitor 17-AAG, can modify the phosphorylation state of proteins and the stability of nuclear proteins, respectively, both of which are likely to impinge on the functional role of LEMD1 within the nucleus.
Proteasome inhibitors such as Bortezomib and MG-132 might lead to the accumulation of regulatory proteins that can negatively influence LEMD1's activity by preventing the degradation of proteins that interact with or regulate LEMD1. The inhibition of PARP by Olaparib could also affect LEMD1 by changing the chromatin domains where LEMD1 is operational, given the role of PARP in DNA repair and chromatin modification. The influence of caffeine, acting as a phosphodiesterase inhibitor, raises the levels of cAMP, which in turn can modulate PKA activity and potentially affect the phosphorylation-dependent activity of LEMD1. Lastly, Camptothecin, by inhibiting topoisomerase I, leads to DNA damage and could compromise the function of LEMD1 in response to genotoxic stress, leading to diminished activity of LEMD1 as part of the cellular damage response. Collectively, these chemical inhibitors, through their targeted interference in various biochemical pathways, contribute to the indirect inhibition of LEMD1 activity, crucial for maintaining nuclear integrity and functionality.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR (mammalian target of rapamycin) which is essential for protein synthesis and cell growth. As LEMD1 is involved in the regulation of the cell cycle, rapamycin's inhibition of mTOR can lead to a reduction in cell proliferation, which could diminish the functional activity of LEMD1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor. PI3K is upstream of Akt signaling, which can regulate nuclear processes and potentially influence proteins like LEMD1 that are involved in chromatin organization and nuclear integrity. By inhibiting PI3K, wortmannin could indirectly lead to diminished functional activity of LEMD1. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). Since LEMD1 is associated with chromatin structure, inhibiting HDAC can alter the acetylation state of histones, potentially affecting the cellular localization or function of LEMD1 by changing the chromatin landscape where LEMD1 operates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. The MAPK/ERK pathway is implicated in numerous nuclear events. Inhibition of this pathway by PD 98059 could indirectly affect the role of LEMD1 in the nucleus by altering the phosphorylation state of proteins that interact with or regulate LEMD1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is another inhibitor of PI3K, like Wortmannin, and it would have similar effects in potentially diminishing the activity of LEMD1 by affecting upstream Akt signaling pathways that influence nuclear protein function. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an Hsp90 inhibitor. Hsp90 is involved in the proper folding and function of many nuclear proteins. By inhibiting Hsp90, 17-AAG may affect the stability and function of LEMD1 if it is a client protein of Hsp90, leading to a decrease in LEMD1's functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By preventing the degradation of proteins, bortezomib could indirectly affect LEMD1’s functional activity by causing an accumulation of proteins that may regulate or modify LEMD1's function or localization. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor and would potentially diminish LEMD1 activity by the same mechanism of action, causing an accumulation of proteins within the cell that could negatively regulate LEMD1. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a PARP inhibitor. While primarily implicated in DNA repair, PARP inhibition can also affect chromatin structure and the function of proteins associated with it. Inhibition of PARP may indirectly lead to diminished LEMD1 activity if LEMD1 operates within PARP-influenced chromatin domains. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine is a known inhibitor of phosphodiesterases, leading to an increase in cAMP. Elevated cAMP can affect PKA activity, which may influence nuclear protein function. If LEMD1 activity is modulated by PKA-dependent phosphorylation, caffeine could indirectly diminish its functional activity. | ||||||